Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.

Vertex exec Ian Smith only just stepped into the company’s interim CFO role alongside his COO title. But now, he’s been fired from both positions.

Oschmann bases his rosy forecast on China's recent work streamlining its drug evaluation process and adopting new policies for IP protection.

GSK investors cheered when the company said it would spin off its consumer unit. But the company’s Tesaro buy didn’t sit so well at first.